spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  antibody drug conjugate 

 HSMN NewsFeed - 22 Aug 2022
Biosion, Inc. Appoints Steven Knapp, Pharm.D. as Chief Regulatory & Quality Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2022
Sobi to license loncastuximab tesirine from ADC Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Apr 2022
Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2021
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Dec 2019
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 May 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2018
BioAtla Appoints Scott Smith As President
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Jul 2018
BioAtla Appoints Lawrence Fong, M.D. As Scientific Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Jun 2018
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Apr 2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Aug 2016
Ambrx Closes $45M Round of Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Apr 2016
Pliant Therapeutics Expands Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2015
Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Sep 2015
ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2015
Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Jul 2015
SutroVax raises $22 million in Series A
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 7 Jan 2015
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin(TM) Platform for Cancer Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 Dec 2014
Crescendo Biologics' Receives Further Investment from Astellas Venture Management to Develop Novel Humabody(TM) Therapeutics Targeting Immune Checkpoint Inhibitors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2014
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody(TM) Therapeutics Against Multiple Immuno-Oncology Targets
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2014
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2014
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jan 2014
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Oct 2013
Immune Pharmaceuticals Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 26 Jul 2013
Meditope Biosciences Raises $3.6M in Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 May 2013
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2013
Ambrx Appoints Lawson Macartney, Ph.D., DVM, Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Oct 2012
Sutro Biopharma Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 May 2012
Sutro Closes $16.5 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Jun 2011
Esperance Pharmaceuticals Completes $7.5 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 May 2011
Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Apr 2011
Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Mar 2008
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
antibody drug conjugate
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.